Comparing the immune response to a novel intranasal nanoparticle PLGA vaccine and a commercial BPI3V vaccine in dairy calves

BMC Veterinary Research

Michael D. Welsh¹  Simon Doherty¹  Bryan Markey³  Joseph P. Cassidy³  Bernadette Earley²  Fawad Mansoor³ 

[1] Present address: SiSaf Ltd, Innovation Centre, Northern Ireland Science Park, Queen’s Island, Belfast BT3 9DT, UK;Animal and Bioscience Research Department, Animal & Grassland Research and Innovation Centre, Teagasc, Grange, Dunsany, Co. Meath, Ireland;Veterinary Sciences Centre, School of Agriculture, Food Science and Veterinary Medicine, University College Dublin, Belfield, Ireland

关键词: Bovine respiratory disease;    Vaccine;    Livestock;    PLGA;    Nanoparticle;   

Others  :  1224293
DOI  :  10.1186/s12917-015-0481-y

 received in 2015-01-09, accepted in 2015-07-13,  发布年份 2015

【 摘 要 】

Background

There is a need to improve vaccination against respiratory pathogens in calves by stimulation of local immunity at the site of pathogen entry at an early stage in life. Ideally such a vaccine preparation would not be inhibited by the maternally derived antibodies. Additionally, localized immune response at the site of infection is also crucial to control infection at the site of entry of virus. The present study investigated the response to an intranasal bovine parainfluenza 3 virus (BPI3V) antigen preparation encapsulated in PLGA (poly dl-lactic-co-glycolide) nanoparticles in the presence of pre-existing anti-BPI3V antibodies in young calves and comparing it to a commercially available BPI3V respiratory vaccine.

Results

There was a significant (P < 0.05) increase in BPI3V-specific IgA in the nasal mucus of the BPI3V nanoparticle vaccine group alone. Following administration of the nanoparticle vaccine an early immune response was induced that continued to grow until the end of study and was not observed in the other treatment groups. Virus specific serum IgG response to both the nanoparticle vaccine and commercial live attenuated vaccine showed a significant (P < 0.05) rise over the period of study. However, the cell mediated immune response observed didn’t show any significant rise in any of the treatment groups.

Conclusion

Calves administered the intranasal nanoparticle vaccine induced significantly greater mucosal IgA responses, compared to the other treatment groups. This suggests an enhanced, sustained mucosal-based immunological response to the BPI3V nanoparticle vaccine in the face of pre-existing antibodies to BPI3V, which are encouraging and potentially useful characteristics of a candidate vaccine. However, ability of nanoparticle vaccine in eliciting cell mediated immune response needs further investigation. More sustained local mucosal immunity induced by nanoparticle vaccine has obvious potential if it translates into enhanced protective immunity in the face of virus outbreak.

【 授权许可】

   
2015 Mansoor et al.

【 图 表 】

Fig. 1.

Fig. 2.

【 参考文献 】

• [1]Adair BM. Nanoparticle vaccines against respiratory viruses. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2009; 1(4):405-414.
• [2]Crowe JE. Influence of maternal antibodies on neonatal immunization against respiratory viruses. Clin Infect Dis. 2001; 33(10):1720-1727.
• [3]Menanteau-Horta A, Ames T, Johnson D, Meiske J. Effect of maternal antibody upon vaccination with infectious bovine rhinotracheitis and bovine virus diarrhea vaccines. Can J Comp Med. 1985; 49(1):10-14.
• [4]Kimman TG, Westenbrink F, Schreuder BEC, Straver PJ. Local and systemic antibody-response to bovine respiratory syncytial virus-infection and reinfection in calves with and without maternal antibodies. J Clin Microbiol. 1987; 25(6):1097-1106.
• [5]Morein B, Abusugra I, Blomqvist G. Immunity in neonates. Vet Immunol Immunopathol. 2002; 87(3–4):207-213.
• [6]Morein B, Blomqvist G, Hu K. Immune responsiveness in the neonatal period. J Comp Pathol. 2007; 137:27-31.
• [7]Shewen PE, Carrasco-Medina L, McBey BA, Hodgins DC. Challenges in mucosal vaccination of cattle. Vet Immunol Immunopathol. 2009; 128(1–3):192-198.
• [8]Mansoor F, Earley B, Cassidy JP, Markey B, Foster C, Doherty S et al.. Intranasal delivery of nanoparticles encapsulating BPI3V proteins induces an early humoral immune response in mice. Res Vet Sci. 2014; 96(3):551-557.
• [9]Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm. 2008; 5(4):505-515.
• [10]Kavanagh OV, Earley B, Murray M, Foster CJ, Adair BM. Antigen-specific IgA and IgG responses in calves inoculated intranasally with ovalbumin encapsulated in poly(DL-lactide-co-glycolide) microspheres. Vaccine. 2003; 21(27–30):4472-4480.
• [11]Chen HM. Recent advances in mucosal vaccine development. J Control Release. 2000; 67(2–3):117-128.
• [12]Zinkernagel RM, Ehl S, Aichele P, Oehen S, Kündig T, Hengartner H. Antigen localisation regulates immune responses in a dose‐and time‐dependent fashion: a geographical view of immune reactivity. Immunol Rev. 1997; 156(1):199-209.
• [13]Zinkernagel RM. Localization dose and time of antigens determine immune reactivity. In: 2000: Elsevier; 2000: 163–71.
• [14]Liebler-Tenorio EM, Pabst R. MALT structure and function in farm animals. Vet Res. 2006; 37(3):257-280.
• [15]Higaki M, Azechi Y, Takase T, Igarashi R, Nagahara S, Sano A et al.. Collagen minipellet as a controlled release delivery system for tetanus and diphtheria toxoid. Vaccine. 2001; 19(23–24):3091-3096.
• [16]Lofthouse S. Immunological aspects of controlled antigen delivery. Adv Drug Deliv Rev. 2002; 54(6):863-870.
• [17]Garinot M, Fievez V, Pourcelle V, Stoffelbach F, des Rieux A, Plapied L et al.. PEGylated PLGA-based nanoparticles targeting M cells for oral vaccination. J Control Release. 2007; 120(3):195-204.
• [18]Buonaguro FM, Tornesello ML, Buonaguro L. New adjuvants in evolving vaccine strategies. Expert Opin Biol Ther. 2011; 11(7):827-832.
• [19]Kwon YJ, Standley SM, Goh SL, Frechet JMJ. Enhanced antigen presentation and immunostimulation of dendritic cells using acid-degradable cationic nanoparticles. J Control Release. 2005; 105(3):199-212.
• [20]Vila A, Sanchez A, Perez C, Alonso MJ. PLA-PEG nanospheres: New carriers for transmucosal delivery of proteins and plasmid DNA. Polymer Adv Tech. 2002; 13(10–12):851-858.
• [21]Tahara K, Sakai T, Yamamoto H, Takeuchi H, Hirashima N, Kawashima Y. Improved cellular uptake of chitosan-modi fled PLGA nanospheres by A549 cells. Int J Pharm. 2009; 382(1–2):198-204.
• [22]Bryson DG, Adair BM, McNulty MS, McAliskey M, Bradford HEL, Allan GM et al.. Studies on the efficacy of intranasal vaccination for the prevention of experimentally induced parainfluenza type 3 virus pneumonia in calves. Vet Rec. 1999; 145(2):33-39.
• [23]Vangeel I, Ioannou F, Riegler L, Salt JS, Harmeyer SS. Efficacy of an intranasal modified live bovine respiratory syncytial virus and temperature-sensitive parainfluenza type 3 virus vaccine in 3-week-old calves experimentally challenged with PI3V. Vet J. 2009; 179(1):101-108.
• [24]Siegrist CA, Cordova M, Brandt C, Barrios C, Berney M, Tougne C et al.. Determinants of infant responses to vaccines in presence of maternal antibodies. Vaccine. 1998; 16(14–15):1409-1414.
• [25]Lee MS, Greenberg DP, Yeh SH, Yogev R, Reisinger KS, Ward JI et al.. Antibody responses to bovine parainfluenza virus type 3 (PIV3) vaccination and human PIV3 infection in young infants. J Infect Dis. 2001; 184(7):909-913.
• [26]Greenberg DP, Walker RE, Lee MS, Reisinger KS, Ward JI, Yogev R et al.. A bovine parainfluenza virus type 3 vaccine is safe and immunogenic in early infancy. J Infect Dis. 2005; 191(7):1116-1122.
• [27]Bradshaw BJF, Edwards S. Antibody isotype responses to experimental infection with bovine herpesvirus 1 in calves with colostrally derived antibody. Vet Microbiol. 1996; 53(1–2):143-151.
• [28]Peters AR, Thevasagayam SJ, Wiseman A, Salt JS. Duration of immunity of a quadrivalent vaccine against respiratory diseases caused by BHV-1, PI3V, BVDV, and BRSV in experimentally infected calves. Prev Vet Med. 2004; 66(1–4):63-77.
• [29]Salt JS, Thevasagayam SJ, Wiseman A, Peters AR. Efficacy of a quadrivalent vaccine against respiratory diseases caused by BHV-1, PI(3)V, BVDV and BRSV in experimentally infected calves. Vet J. 2007; 174(3):616-626.
• [30]Pollock J, Welsh M. The WC1+ [gamma][delta] T-cell population in cattle: a possible role in resistance to intracellular infection. Vet Immunol Immunopathol. 2002; 89(3–4):105-114.
• [31]Phillips J, Everson M, Moldoveanu Z, Lue C, Mestecky J. Synergistic effect of IL-4 and IFN-gamma on the expression of polymeric Ig receptor (secretory component) and IgA binding by human epithelial cells. J Immunol. 1990; 145(6):1740-1744.
• [32]Pilette C, Ouadrhiri Y, Godding V, Vaerman JP, Sibille Y. Lung mucosal immunity: immunoglobulin-A revisited. Eur Respir J. 2001; 18(3):571-588.
• [33]Song CX, Labhasetwar V, Murphy H, Qu X, Humphrey WR, Shebuski RJ et al.. Formulation and characterization of biodegradable nanoparticles for intravascular local drug delivery. J Control Release. 1997; 43(2–3):197-212.
• [34]Hans ML, Lowman AM. Biodegradable nanoparticles for drug delivery and targeting. Curr Opin Solid State Mater Sci. 2002; 6(4):319-327.
• [35]Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD et al.. Measurement of protein using bicinchoninic acid. Anal Biochem. 1985; 150(1):76-85.
• [36]Wiechelman KJ, Braun RD, Fitzpatrick JD. Investigation of the bicinchoninic acid protein assay - identification of the groups responsible for color formation. Anal Biochem. 1988; 175(1):231-237.
• [37]Brown RE, Jarvis KL, Hyland KJ. Protein measurement using bicinchoninic acid - elimination of interfering substances. Anal Biochem. 1989; 180(1):136-139.
• [38]Wood PR, Corner LA, Plackett P. Development of a simple, rapid invitro cellular-assay for bovine tuberculosis based on the production of gamma-interferon. Res Vet Sci. 1990; 49(1):46-–9.